| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Brachytherapy | 75 | 2023 | 1005 | 14.920 |
Why?
|
| Proton Therapy | 64 | 2024 | 1637 | 10.880 |
Why?
|
| Prostatic Neoplasms | 105 | 2023 | 5869 | 8.470 |
Why?
|
| Radiotherapy, Intensity-Modulated | 67 | 2024 | 2178 | 6.920 |
Why?
|
| Head and Neck Neoplasms | 74 | 2024 | 4148 | 6.540 |
Why?
|
| Oropharyngeal Neoplasms | 36 | 2022 | 1162 | 5.750 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 48 | 2024 | 2459 | 3.640 |
Why?
|
| Radiotherapy Dosage | 79 | 2024 | 4020 | 3.410 |
Why?
|
| Magnetic Resonance Imaging | 42 | 2023 | 7916 | 3.190 |
Why?
|
| Radiation Injuries | 24 | 2020 | 1476 | 3.110 |
Why?
|
| Prostate | 24 | 2023 | 1090 | 3.070 |
Why?
|
| Iodine Radioisotopes | 18 | 2023 | 388 | 2.960 |
Why?
|
| Eye Neoplasms | 9 | 2024 | 257 | 2.450 |
Why?
|
| Carcinoma, Adenoid Cystic | 10 | 2024 | 444 | 2.240 |
Why?
|
| Radiosurgery | 13 | 2023 | 1389 | 2.130 |
Why?
|
| Radiation Oncology | 10 | 2021 | 558 | 2.110 |
Why?
|
| Carcinoma, Squamous Cell | 37 | 2024 | 5604 | 2.090 |
Why?
|
| Xerostomia | 7 | 2021 | 205 | 2.040 |
Why?
|
| Radiotherapy, Image-Guided | 14 | 2020 | 340 | 2.010 |
Why?
|
| Nasopharyngeal Neoplasms | 12 | 2023 | 340 | 2.000 |
Why?
|
| Lacrimal Apparatus Diseases | 7 | 2024 | 144 | 1.960 |
Why?
|
| Alphapapillomavirus | 6 | 2022 | 172 | 1.890 |
Why?
|
| Palladium | 7 | 2023 | 56 | 1.860 |
Why?
|
| Papillomavirus Infections | 12 | 2021 | 999 | 1.820 |
Why?
|
| Quality Assurance, Health Care | 8 | 2020 | 593 | 1.820 |
Why?
|
| Nomograms | 7 | 2021 | 312 | 1.820 |
Why?
|
| Radioisotopes | 7 | 2020 | 176 | 1.740 |
Why?
|
| Photons | 7 | 2020 | 536 | 1.710 |
Why?
|
| Male | 210 | 2024 | 128479 | 1.640 |
Why?
|
| Humans | 301 | 2024 | 270713 | 1.580 |
Why?
|
| Lacrimal Apparatus | 6 | 2024 | 185 | 1.520 |
Why?
|
| Quality of Life | 24 | 2023 | 4810 | 1.470 |
Why?
|
| Radiometry | 18 | 2022 | 1021 | 1.440 |
Why?
|
| Phantoms, Imaging | 12 | 2020 | 1330 | 1.440 |
Why?
|
| Re-Irradiation | 8 | 2021 | 166 | 1.370 |
Why?
|
| Prostatectomy | 11 | 2023 | 1003 | 1.350 |
Why?
|
| Neoplasm Recurrence, Local | 40 | 2024 | 10404 | 1.340 |
Why?
|
| Organs at Risk | 13 | 2023 | 559 | 1.300 |
Why?
|
| Patient Reported Outcome Measures | 11 | 2020 | 879 | 1.290 |
Why?
|
| Prostate-Specific Antigen | 21 | 2023 | 1030 | 1.280 |
Why?
|
| Organ Sparing Treatments | 6 | 2019 | 283 | 1.200 |
Why?
|
| Papillomaviridae | 11 | 2022 | 636 | 1.200 |
Why?
|
| Carcinoma | 12 | 2023 | 2610 | 1.190 |
Why?
|
| Magnetic Resonance Imaging, Interventional | 5 | 2020 | 106 | 1.150 |
Why?
|
| Radiation Dosage | 12 | 2022 | 1042 | 1.120 |
Why?
|
| Aged | 126 | 2024 | 73613 | 1.110 |
Why?
|
| Middle Aged | 130 | 2024 | 90533 | 1.070 |
Why?
|
| Rectum | 7 | 2020 | 480 | 1.060 |
Why?
|
| Fiducial Markers | 3 | 2016 | 95 | 1.050 |
Why?
|
| Health Care Costs | 7 | 2021 | 696 | 1.000 |
Why?
|
| Urination Disorders | 5 | 2018 | 63 | 1.000 |
Why?
|
| Prospective Studies | 39 | 2022 | 13419 | 0.960 |
Why?
|
| Image Processing, Computer-Assisted | 8 | 2020 | 1691 | 0.950 |
Why?
|
| Tomography, X-Ray Computed | 27 | 2023 | 7787 | 0.920 |
Why?
|
| Cost-Benefit Analysis | 4 | 2018 | 966 | 0.920 |
Why?
|
| Radiotherapy | 11 | 2018 | 1858 | 0.910 |
Why?
|
| Eyelid Neoplasms | 7 | 2015 | 193 | 0.900 |
Why?
|
| Seminal Vesicles | 5 | 2020 | 149 | 0.880 |
Why?
|
| Algorithms | 15 | 2021 | 3906 | 0.880 |
Why?
|
| Protons | 8 | 2023 | 480 | 0.870 |
Why?
|
| Radiotherapy, Conformal | 10 | 2020 | 898 | 0.860 |
Why?
|
| Deglutition Disorders | 6 | 2020 | 488 | 0.850 |
Why?
|
| Androgen Antagonists | 13 | 2023 | 420 | 0.840 |
Why?
|
| Follow-Up Studies | 37 | 2023 | 15275 | 0.830 |
Why?
|
| Acetylcysteine | 2 | 2014 | 133 | 0.830 |
Why?
|
| Adult | 92 | 2024 | 82041 | 0.820 |
Why?
|
| Retrospective Studies | 77 | 2024 | 39959 | 0.820 |
Why?
|
| Pelvis | 2 | 2023 | 381 | 0.800 |
Why?
|
| Adenocarcinoma | 14 | 2024 | 7920 | 0.800 |
Why?
|
| Treatment Outcome | 55 | 2024 | 33847 | 0.800 |
Why?
|
| Aged, 80 and over | 64 | 2024 | 31116 | 0.780 |
Why?
|
| Nose Neoplasms | 4 | 2023 | 243 | 0.780 |
Why?
|
| Simulation Training | 2 | 2020 | 162 | 0.750 |
Why?
|
| Relative Biological Effectiveness | 4 | 2021 | 227 | 0.720 |
Why?
|
| Laryngeal Neoplasms | 7 | 2021 | 530 | 0.720 |
Why?
|
| Ophthalmologic Surgical Procedures | 3 | 2018 | 141 | 0.710 |
Why?
|
| Erectile Dysfunction | 2 | 2014 | 240 | 0.710 |
Why?
|
| Penis | 2 | 2012 | 143 | 0.700 |
Why?
|
| Urethral Diseases | 1 | 2020 | 38 | 0.700 |
Why?
|
| Lower Urinary Tract Symptoms | 1 | 2020 | 39 | 0.700 |
Why?
|
| Taste | 2 | 2022 | 54 | 0.680 |
Why?
|
| Research Design | 2 | 2018 | 1562 | 0.680 |
Why?
|
| Female | 108 | 2024 | 148885 | 0.670 |
Why?
|
| Radiotherapy, Computer-Assisted | 3 | 2012 | 127 | 0.660 |
Why?
|
| Urinary Bladder | 7 | 2020 | 592 | 0.660 |
Why?
|
| Chemoradiotherapy | 12 | 2021 | 2037 | 0.650 |
Why?
|
| Dysgeusia | 1 | 2018 | 6 | 0.650 |
Why?
|
| Ageusia | 1 | 2018 | 3 | 0.640 |
Why?
|
| Parotid Gland | 3 | 2019 | 111 | 0.640 |
Why?
|
| Radiation-Sensitizing Agents | 2 | 2021 | 368 | 0.630 |
Why?
|
| Urethra | 5 | 2020 | 167 | 0.630 |
Why?
|
| Education, Medical, Continuing | 1 | 2020 | 230 | 0.630 |
Why?
|
| Rectal Diseases | 3 | 2018 | 57 | 0.620 |
Why?
|
| Indazoles | 1 | 2020 | 310 | 0.610 |
Why?
|
| Cesium Radioisotopes | 1 | 2017 | 38 | 0.600 |
Why?
|
| Survival Rate | 32 | 2024 | 12530 | 0.600 |
Why?
|
| Contrast Media | 5 | 2020 | 1505 | 0.580 |
Why?
|
| Physicians | 5 | 2020 | 854 | 0.580 |
Why?
|
| Disease-Free Survival | 25 | 2023 | 10268 | 0.560 |
Why?
|
| Vaginal Neoplasms | 3 | 2008 | 152 | 0.560 |
Why?
|
| Radiotherapy, Adjuvant | 14 | 2023 | 2272 | 0.550 |
Why?
|
| Cisplatin | 7 | 2023 | 2508 | 0.540 |
Why?
|
| Robotic Surgical Procedures | 2 | 2023 | 536 | 0.540 |
Why?
|
| Orbital Neoplasms | 2 | 2015 | 234 | 0.530 |
Why?
|
| Societies, Medical | 3 | 2020 | 1323 | 0.520 |
Why?
|
| Osteoradionecrosis | 1 | 2017 | 128 | 0.520 |
Why?
|
| Skull Base Neoplasms | 6 | 2023 | 339 | 0.510 |
Why?
|
| Orbit | 2 | 2024 | 209 | 0.510 |
Why?
|
| Penile Erection | 2 | 2014 | 88 | 0.500 |
Why?
|
| Poly(ADP-ribose) Polymerase Inhibitors | 1 | 2020 | 521 | 0.500 |
Why?
|
| Piperidines | 2 | 2020 | 1099 | 0.490 |
Why?
|
| Patient Selection | 5 | 2019 | 2029 | 0.480 |
Why?
|
| Time Factors | 21 | 2024 | 12978 | 0.480 |
Why?
|
| Phosphodiesterase 5 Inhibitors | 1 | 2014 | 21 | 0.480 |
Why?
|
| Randomized Controlled Trials as Topic | 4 | 2021 | 2658 | 0.480 |
Why?
|
| Carbolines | 1 | 2014 | 30 | 0.470 |
Why?
|
| Neoplasm Staging | 32 | 2021 | 14033 | 0.470 |
Why?
|
| Uncertainty | 6 | 2024 | 327 | 0.470 |
Why?
|
| Patient Preference | 1 | 2016 | 230 | 0.450 |
Why?
|
| Particle Accelerators | 1 | 2016 | 362 | 0.440 |
Why?
|
| Internship and Residency | 4 | 2020 | 1442 | 0.440 |
Why?
|
| Paranasal Sinus Neoplasms | 3 | 2023 | 294 | 0.440 |
Why?
|
| Cobalt | 2 | 2010 | 57 | 0.430 |
Why?
|
| Neoplasms, Unknown Primary | 2 | 2018 | 199 | 0.430 |
Why?
|
| Urination | 1 | 2013 | 34 | 0.430 |
Why?
|
| Insurance Coverage | 4 | 2020 | 275 | 0.420 |
Why?
|
| Tonsillar Neoplasms | 3 | 2022 | 81 | 0.410 |
Why?
|
| Combined Modality Therapy | 17 | 2020 | 9053 | 0.410 |
Why?
|
| Health Status | 4 | 2014 | 626 | 0.400 |
Why?
|
| Dose-Response Relationship, Radiation | 8 | 2016 | 751 | 0.400 |
Why?
|
| Cohort Studies | 18 | 2021 | 9463 | 0.390 |
Why?
|
| Computers | 2 | 2021 | 132 | 0.390 |
Why?
|
| Radiation Tolerance | 4 | 2021 | 639 | 0.380 |
Why?
|
| Esthesioneuroblastoma, Olfactory | 3 | 2017 | 124 | 0.380 |
Why?
|
| Health Services Accessibility | 3 | 2024 | 819 | 0.380 |
Why?
|
| Observer Variation | 3 | 2021 | 709 | 0.370 |
Why?
|
| Salvage Therapy | 8 | 2023 | 2124 | 0.370 |
Why?
|
| Survival Analysis | 18 | 2020 | 9281 | 0.370 |
Why?
|
| Salivary Gland Neoplasms | 3 | 2021 | 497 | 0.360 |
Why?
|
| Monitoring, Intraoperative | 1 | 2012 | 265 | 0.360 |
Why?
|
| Hypesthesia | 1 | 2010 | 22 | 0.360 |
Why?
|
| Surveys and Questionnaires | 11 | 2020 | 5923 | 0.350 |
Why?
|
| United States | 24 | 2024 | 15828 | 0.350 |
Why?
|
| Urinary Catheterization | 1 | 2011 | 135 | 0.350 |
Why?
|
| Texas | 10 | 2018 | 6446 | 0.350 |
Why?
|
| Cell Line, Tumor | 9 | 2021 | 14878 | 0.350 |
Why?
|
| Esophagitis | 2 | 2022 | 210 | 0.340 |
Why?
|
| Prosthesis Implantation | 1 | 2012 | 243 | 0.340 |
Why?
|
| Prognosis | 23 | 2021 | 22528 | 0.340 |
Why?
|
| Tumor Cells, Cultured | 1 | 2016 | 5759 | 0.330 |
Why?
|
| Neoplasms | 8 | 2024 | 15949 | 0.320 |
Why?
|
| Skull Base | 6 | 2021 | 224 | 0.320 |
Why?
|
| Positron-Emission Tomography | 8 | 2022 | 2199 | 0.320 |
Why?
|
| Cancer Care Facilities | 6 | 2016 | 907 | 0.320 |
Why?
|
| Radiotherapy Setup Errors | 3 | 2020 | 85 | 0.320 |
Why?
|
| Lymphatic Metastasis | 14 | 2022 | 4969 | 0.320 |
Why?
|
| DNA Repair | 4 | 2021 | 1906 | 0.310 |
Why?
|
| Organ Size | 2 | 2020 | 686 | 0.310 |
Why?
|
| Adenoma, Pleomorphic | 2 | 2020 | 63 | 0.310 |
Why?
|
| Body Burden | 1 | 2008 | 64 | 0.300 |
Why?
|
| Printing, Three-Dimensional | 2 | 2020 | 144 | 0.300 |
Why?
|
| Mouth Neoplasms | 3 | 2017 | 735 | 0.290 |
Why?
|
| Stomatitis | 4 | 2018 | 190 | 0.290 |
Why?
|
| Artifacts | 3 | 2020 | 537 | 0.290 |
Why?
|
| Induction Chemotherapy | 4 | 2021 | 679 | 0.280 |
Why?
|
| Radiography | 5 | 2016 | 1994 | 0.280 |
Why?
|
| Clinical Competence | 3 | 2020 | 1331 | 0.280 |
Why?
|
| Diethylstilbestrol | 1 | 2007 | 165 | 0.280 |
Why?
|
| Tumor Burden | 7 | 2017 | 2033 | 0.280 |
Why?
|
| Young Adult | 22 | 2021 | 22243 | 0.270 |
Why?
|
| Visual Acuity | 4 | 2018 | 867 | 0.260 |
Why?
|
| Healthcare Disparities | 2 | 2024 | 657 | 0.260 |
Why?
|
| Preoperative Care | 1 | 2012 | 1581 | 0.260 |
Why?
|
| Cone-Beam Computed Tomography | 4 | 2020 | 208 | 0.260 |
Why?
|
| Blood Transfusion | 2 | 2021 | 580 | 0.250 |
Why?
|
| Workflow | 3 | 2021 | 278 | 0.250 |
Why?
|
| Probability | 4 | 2022 | 886 | 0.240 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 2 | 2018 | 508 | 0.240 |
Why?
|
| Glottis | 2 | 2019 | 68 | 0.240 |
Why?
|
| Monte Carlo Method | 5 | 2021 | 708 | 0.230 |
Why?
|
| Computer Simulation | 3 | 2020 | 1568 | 0.230 |
Why?
|
| Neoplasm Invasiveness | 6 | 2018 | 4054 | 0.230 |
Why?
|
| Apoptosis | 5 | 2021 | 7755 | 0.230 |
Why?
|
| Submandibular Gland Neoplasms | 2 | 2015 | 37 | 0.230 |
Why?
|
| Scattering, Radiation | 2 | 2016 | 334 | 0.220 |
Why?
|
| Longitudinal Studies | 3 | 2019 | 2051 | 0.220 |
Why?
|
| Radiation Oncologists | 1 | 2023 | 32 | 0.220 |
Why?
|
| Radiotherapy, High-Energy | 3 | 2014 | 303 | 0.220 |
Why?
|
| Lymph Nodes | 6 | 2019 | 3081 | 0.220 |
Why?
|
| Risk Factors | 14 | 2020 | 17861 | 0.220 |
Why?
|
| Models, Theoretical | 3 | 2016 | 799 | 0.220 |
Why?
|
| Stents | 2 | 2020 | 1002 | 0.220 |
Why?
|
| Medical Oncology | 6 | 2020 | 1464 | 0.220 |
Why?
|
| Risk Assessment | 10 | 2021 | 6766 | 0.220 |
Why?
|
| Imaging, Three-Dimensional | 5 | 2020 | 906 | 0.220 |
Why?
|
| Carcinoma, Merkel Cell | 2 | 2015 | 172 | 0.210 |
Why?
|
| Positron Emission Tomography Computed Tomography | 3 | 2018 | 881 | 0.210 |
Why?
|
| Neoplasm Grading | 8 | 2019 | 1828 | 0.210 |
Why?
|
| Neck Dissection | 3 | 2015 | 294 | 0.210 |
Why?
|
| Signal-To-Noise Ratio | 2 | 2020 | 128 | 0.210 |
Why?
|
| Watchful Waiting | 2 | 2015 | 293 | 0.210 |
Why?
|
| Comorbidity | 4 | 2020 | 2393 | 0.210 |
Why?
|
| DNA Damage | 3 | 2021 | 1991 | 0.210 |
Why?
|
| Travel | 1 | 2024 | 191 | 0.210 |
Why?
|
| Practice Patterns, Physicians' | 4 | 2020 | 1301 | 0.210 |
Why?
|
| Cell Survival | 3 | 2021 | 3057 | 0.210 |
Why?
|
| Academic Medical Centers | 2 | 2016 | 682 | 0.200 |
Why?
|
| Ependymoma | 2 | 2023 | 264 | 0.200 |
Why?
|
| Tongue Neoplasms | 3 | 2020 | 253 | 0.200 |
Why?
|
| Risk | 4 | 2017 | 1930 | 0.200 |
Why?
|
| Radiodermatitis | 2 | 2019 | 79 | 0.200 |
Why?
|
| Patient-Centered Care | 2 | 2016 | 319 | 0.200 |
Why?
|
| Maxillary Sinus Neoplasms | 1 | 2023 | 114 | 0.200 |
Why?
|
| Insurance, Health, Reimbursement | 2 | 2019 | 66 | 0.190 |
Why?
|
| Reproducibility of Results | 7 | 2019 | 6193 | 0.190 |
Why?
|
| G2 Phase Cell Cycle Checkpoints | 1 | 2021 | 78 | 0.190 |
Why?
|
| Thyroid Carcinoma, Anaplastic | 1 | 2024 | 291 | 0.190 |
Why?
|
| Radiobiology | 1 | 2021 | 56 | 0.190 |
Why?
|
| Taste Buds | 1 | 2020 | 8 | 0.190 |
Why?
|
| Ubiquitin-Specific Proteases | 1 | 2021 | 71 | 0.190 |
Why?
|
| Retinal Diseases | 1 | 2023 | 192 | 0.190 |
Why?
|
| Pharyngeal Neoplasms | 2 | 2013 | 142 | 0.180 |
Why?
|
| Health Resources | 2 | 2019 | 170 | 0.180 |
Why?
|
| Necrosis | 2 | 2021 | 591 | 0.180 |
Why?
|
| Rad51 Recombinase | 1 | 2021 | 125 | 0.180 |
Why?
|
| Mixed Tumor, Malignant | 1 | 2020 | 19 | 0.180 |
Why?
|
| Clinical Protocols | 2 | 2018 | 476 | 0.180 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 9 | 2023 | 16741 | 0.180 |
Why?
|
| Entropy | 1 | 2020 | 36 | 0.180 |
Why?
|
| Parotid Neoplasms | 3 | 2019 | 150 | 0.180 |
Why?
|
| Lung Neoplasms | 7 | 2022 | 12039 | 0.180 |
Why?
|
| Caspase 8 | 1 | 2020 | 146 | 0.180 |
Why?
|
| Prostheses and Implants | 3 | 2011 | 291 | 0.180 |
Why?
|
| Carcinoma, Ductal | 1 | 2021 | 144 | 0.180 |
Why?
|
| Sebaceous Gland Neoplasms | 2 | 2011 | 100 | 0.180 |
Why?
|
| Disease Progression | 6 | 2024 | 6881 | 0.180 |
Why?
|
| Practice Guidelines as Topic | 5 | 2013 | 2395 | 0.180 |
Why?
|
| Endpoint Determination | 2 | 2018 | 180 | 0.170 |
Why?
|
| Operating Rooms | 1 | 2021 | 130 | 0.170 |
Why?
|
| Anatomic Landmarks | 1 | 2020 | 48 | 0.170 |
Why?
|
| Antineoplastic Protocols | 1 | 2020 | 36 | 0.170 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 3 | 2022 | 5582 | 0.170 |
Why?
|
| Dry Eye Syndromes | 1 | 2023 | 261 | 0.170 |
Why?
|
| Wounds, Gunshot | 1 | 2021 | 152 | 0.170 |
Why?
|
| Ferrosoferric Oxide | 1 | 2020 | 39 | 0.170 |
Why?
|
| Cellular Senescence | 2 | 2019 | 389 | 0.170 |
Why?
|
| ROC Curve | 4 | 2018 | 1250 | 0.170 |
Why?
|
| Immobilization | 2 | 2019 | 91 | 0.170 |
Why?
|
| Thiosemicarbazones | 1 | 2019 | 24 | 0.170 |
Why?
|
| Neoadjuvant Therapy | 5 | 2016 | 5246 | 0.170 |
Why?
|
| Uterine Cervical Neoplasms | 3 | 2015 | 1903 | 0.170 |
Why?
|
| Antineoplastic Agents, Hormonal | 3 | 2014 | 841 | 0.170 |
Why?
|
| Orbit Evisceration | 2 | 2024 | 47 | 0.170 |
Why?
|
| Ferric Compounds | 1 | 2020 | 77 | 0.170 |
Why?
|
| Time-to-Treatment | 2 | 2019 | 307 | 0.170 |
Why?
|
| Sarcopenia | 1 | 2021 | 114 | 0.170 |
Why?
|
| Uveal Neoplasms | 1 | 2021 | 194 | 0.160 |
Why?
|
| Ataxia Telangiectasia Mutated Proteins | 1 | 2021 | 437 | 0.160 |
Why?
|
| Adolescent | 15 | 2023 | 32689 | 0.160 |
Why?
|
| Treatment Failure | 3 | 2019 | 1430 | 0.160 |
Why?
|
| Markov Chains | 1 | 2019 | 188 | 0.160 |
Why?
|
| Regression Analysis | 7 | 2020 | 1562 | 0.160 |
Why?
|
| Sensitivity and Specificity | 5 | 2015 | 5157 | 0.160 |
Why?
|
| DNA Breaks, Double-Stranded | 1 | 2021 | 327 | 0.160 |
Why?
|
| Deglutition | 1 | 2020 | 187 | 0.160 |
Why?
|
| Mucositis | 2 | 2016 | 149 | 0.160 |
Why?
|
| Health Facilities | 1 | 2019 | 73 | 0.160 |
Why?
|
| Insurance Claim Review | 1 | 2018 | 74 | 0.160 |
Why?
|
| Self Efficacy | 1 | 2020 | 297 | 0.160 |
Why?
|
| Lymphocytes | 2 | 2020 | 1273 | 0.160 |
Why?
|
| Magnetics | 2 | 2009 | 98 | 0.160 |
Why?
|
| Radiology, Interventional | 1 | 2019 | 141 | 0.150 |
Why?
|
| Thoracic Neoplasms | 2 | 2018 | 363 | 0.150 |
Why?
|
| Clinical Trials, Phase III as Topic | 2 | 2018 | 503 | 0.150 |
Why?
|
| Metal Nanoparticles | 1 | 2020 | 161 | 0.150 |
Why?
|
| Endometrial Neoplasms | 2 | 2019 | 1386 | 0.150 |
Why?
|
| Trigeminal Neuralgia | 1 | 2018 | 42 | 0.150 |
Why?
|
| Fluorodeoxyglucose F18 | 4 | 2018 | 1260 | 0.150 |
Why?
|
| Minocycline | 1 | 2019 | 189 | 0.150 |
Why?
|
| Lymphopenia | 1 | 2020 | 211 | 0.140 |
Why?
|
| Dura Mater | 1 | 2017 | 85 | 0.140 |
Why?
|
| Analysis of Variance | 5 | 2020 | 2315 | 0.140 |
Why?
|
| Body Composition | 2 | 2021 | 602 | 0.140 |
Why?
|
| Clinical Trials, Phase II as Topic | 2 | 2018 | 694 | 0.140 |
Why?
|
| Urologic Diseases | 1 | 2017 | 84 | 0.140 |
Why?
|
| Pancreas | 1 | 2021 | 737 | 0.140 |
Why?
|
| Patient Positioning | 2 | 2019 | 196 | 0.140 |
Why?
|
| Health Status Indicators | 2 | 2017 | 230 | 0.140 |
Why?
|
| Vocal Cords | 1 | 2018 | 106 | 0.140 |
Why?
|
| Health Status Disparities | 1 | 2020 | 321 | 0.140 |
Why?
|
| Nasal Cavity | 1 | 2017 | 155 | 0.140 |
Why?
|
| Olfactory Bulb | 1 | 2017 | 120 | 0.140 |
Why?
|
| Sexual Dysfunction, Physiological | 1 | 2017 | 136 | 0.140 |
Why?
|
| Monitoring, Physiologic | 1 | 2019 | 515 | 0.130 |
Why?
|
| Peer Review | 1 | 2016 | 82 | 0.130 |
Why?
|
| Prevalence | 2 | 2016 | 3395 | 0.130 |
Why?
|
| Oropharynx | 1 | 2016 | 81 | 0.130 |
Why?
|
| Mitosis | 1 | 2018 | 681 | 0.130 |
Why?
|
| Data Display | 1 | 2016 | 49 | 0.130 |
Why?
|
| X-Rays | 1 | 2016 | 151 | 0.130 |
Why?
|
| Pharyngeal Muscles | 1 | 2016 | 40 | 0.130 |
Why?
|
| Peer Review, Health Care | 1 | 2016 | 34 | 0.130 |
Why?
|
| Quality Indicators, Health Care | 2 | 2021 | 355 | 0.130 |
Why?
|
| Neutrophils | 1 | 2020 | 855 | 0.130 |
Why?
|
| Cancer Survivors | 2 | 2020 | 746 | 0.130 |
Why?
|
| Causality | 1 | 2016 | 174 | 0.130 |
Why?
|
| Mandible | 1 | 2017 | 189 | 0.130 |
Why?
|
| Hypopharyngeal Neoplasms | 1 | 2016 | 84 | 0.130 |
Why?
|
| Protein-Tyrosine Kinases | 2 | 2021 | 1837 | 0.130 |
Why?
|
| Socioeconomic Factors | 1 | 2020 | 1250 | 0.130 |
Why?
|
| Gonadotropin-Releasing Hormone | 1 | 2016 | 168 | 0.130 |
Why?
|
| Cell Cycle Proteins | 2 | 2021 | 2112 | 0.130 |
Why?
|
| RNA-Binding Proteins | 1 | 2021 | 1016 | 0.130 |
Why?
|
| Population Surveillance | 1 | 2019 | 631 | 0.130 |
Why?
|
| Attitude of Health Personnel | 2 | 2020 | 899 | 0.120 |
Why?
|
| Radiation Exposure | 1 | 2016 | 71 | 0.120 |
Why?
|
| Myoepithelioma | 1 | 2015 | 30 | 0.120 |
Why?
|
| Kaplan-Meier Estimate | 7 | 2020 | 6257 | 0.120 |
Why?
|
| Tadalafil | 1 | 2014 | 5 | 0.120 |
Why?
|
| Physical Examination | 1 | 2016 | 306 | 0.120 |
Why?
|
| Ultrasonography | 2 | 2019 | 1931 | 0.120 |
Why?
|
| Predictive Value of Tests | 5 | 2014 | 4966 | 0.120 |
Why?
|
| Radiopharmaceuticals | 5 | 2013 | 1342 | 0.120 |
Why?
|
| Memory Disorders | 1 | 2017 | 286 | 0.120 |
Why?
|
| Morbidity | 1 | 2016 | 397 | 0.120 |
Why?
|
| Reference Values | 1 | 2016 | 1127 | 0.120 |
Why?
|
| Clinical Trials as Topic | 2 | 2023 | 3841 | 0.120 |
Why?
|
| Gastrostomy | 1 | 2016 | 197 | 0.120 |
Why?
|
| Proportional Hazards Models | 6 | 2023 | 5099 | 0.120 |
Why?
|
| Hypothyroidism | 1 | 2016 | 207 | 0.120 |
Why?
|
| Curriculum | 1 | 2020 | 911 | 0.120 |
Why?
|
| Pyruvic Acid | 1 | 2015 | 132 | 0.110 |
Why?
|
| Learning Curve | 1 | 2014 | 79 | 0.110 |
Why?
|
| Seminoma | 1 | 2014 | 86 | 0.110 |
Why?
|
| Carotid Arteries | 2 | 2019 | 246 | 0.110 |
Why?
|
| Delivery of Health Care | 1 | 2021 | 850 | 0.110 |
Why?
|
| Fatigue | 3 | 2019 | 1292 | 0.110 |
Why?
|
| Muscle, Skeletal | 2 | 2021 | 1175 | 0.110 |
Why?
|
| Enteral Nutrition | 1 | 2016 | 341 | 0.110 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2018 | 637 | 0.110 |
Why?
|
| Thyroid Neoplasms | 1 | 2024 | 1908 | 0.110 |
Why?
|
| Nasolacrimal Duct | 1 | 2013 | 45 | 0.110 |
Why?
|
| Fear | 1 | 2015 | 259 | 0.110 |
Why?
|
| Antineoplastic Agents | 6 | 2019 | 14638 | 0.110 |
Why?
|
| Evidence-Based Medicine | 3 | 2015 | 1027 | 0.110 |
Why?
|
| Sublingual Gland Neoplasms | 1 | 2012 | 3 | 0.110 |
Why?
|
| Cognitive Dysfunction | 1 | 2017 | 327 | 0.100 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2015 | 606 | 0.100 |
Why?
|
| Temperature | 1 | 2014 | 534 | 0.100 |
Why?
|
| Cross-Sectional Studies | 5 | 2024 | 4494 | 0.100 |
Why?
|
| Genital Neoplasms, Female | 1 | 2019 | 794 | 0.100 |
Why?
|
| Multivariate Analysis | 6 | 2018 | 4317 | 0.100 |
Why?
|
| Vomiting | 1 | 2014 | 359 | 0.100 |
Why?
|
| Delphi Technique | 3 | 2023 | 277 | 0.100 |
Why?
|
| Chordoma | 1 | 2014 | 170 | 0.100 |
Why?
|
| Proteomics | 1 | 2019 | 1425 | 0.100 |
Why?
|
| Coitus | 1 | 2012 | 26 | 0.100 |
Why?
|
| Age Factors | 6 | 2020 | 5441 | 0.100 |
Why?
|
| Nausea | 1 | 2014 | 537 | 0.100 |
Why?
|
| Chondrosarcoma | 1 | 2014 | 213 | 0.100 |
Why?
|
| Cystectomy | 1 | 2016 | 637 | 0.100 |
Why?
|
| Postoperative Period | 1 | 2013 | 666 | 0.100 |
Why?
|
| Biomarkers | 3 | 2022 | 5048 | 0.100 |
Why?
|
| Child | 6 | 2023 | 30560 | 0.100 |
Why?
|
| Synchrotrons | 2 | 2022 | 35 | 0.090 |
Why?
|
| International Agencies | 1 | 2011 | 107 | 0.090 |
Why?
|
| Forecasting | 1 | 2014 | 699 | 0.090 |
Why?
|
| Software | 2 | 2015 | 1357 | 0.090 |
Why?
|
| Ultrasonography, Interventional | 1 | 2014 | 425 | 0.090 |
Why?
|
| Quality of Health Care | 1 | 2016 | 614 | 0.090 |
Why?
|
| Epstein-Barr Virus Infections | 1 | 2015 | 481 | 0.090 |
Why?
|
| Incidence | 4 | 2020 | 5825 | 0.090 |
Why?
|
| Image Enhancement | 2 | 2016 | 553 | 0.090 |
Why?
|
| Signal Transduction | 2 | 2019 | 12042 | 0.090 |
Why?
|
| Pilot Projects | 2 | 2015 | 2856 | 0.090 |
Why?
|
| Tissue Distribution | 1 | 2012 | 920 | 0.090 |
Why?
|
| Glucose | 1 | 2016 | 1214 | 0.090 |
Why?
|
| Neoplasms, Hormone-Dependent | 1 | 2012 | 347 | 0.090 |
Why?
|
| Adenocarcinoma, Sebaceous | 1 | 2011 | 66 | 0.090 |
Why?
|
| Tumor Microenvironment | 1 | 2021 | 3054 | 0.090 |
Why?
|
| Cornea | 1 | 2015 | 681 | 0.090 |
Why?
|
| Anisotropy | 1 | 2010 | 182 | 0.090 |
Why?
|
| Foreign-Body Migration | 1 | 2011 | 122 | 0.090 |
Why?
|
| Urinary Retention | 1 | 2009 | 21 | 0.080 |
Why?
|
| Medicare | 3 | 2020 | 926 | 0.080 |
Why?
|
| Mesothelioma | 1 | 2015 | 558 | 0.080 |
Why?
|
| Anxiety Disorders | 1 | 2015 | 735 | 0.080 |
Why?
|
| Biopsy | 2 | 2014 | 3490 | 0.080 |
Why?
|
| Device Removal | 1 | 2011 | 339 | 0.080 |
Why?
|
| Mass Screening | 2 | 2017 | 1547 | 0.080 |
Why?
|
| Drug Administration Schedule | 1 | 2014 | 3534 | 0.080 |
Why?
|
| Glass | 1 | 2008 | 34 | 0.080 |
Why?
|
| Feasibility Studies | 3 | 2023 | 2360 | 0.080 |
Why?
|
| Nitrates | 1 | 2008 | 46 | 0.080 |
Why?
|
| Acrylates | 1 | 2008 | 33 | 0.080 |
Why?
|
| Cervical Vertebrae | 2 | 2020 | 219 | 0.080 |
Why?
|
| Skin Neoplasms | 2 | 2015 | 4899 | 0.080 |
Why?
|
| Consensus | 3 | 2021 | 1113 | 0.080 |
Why?
|
| SEER Program | 3 | 2019 | 1052 | 0.080 |
Why?
|
| Palliative Care | 2 | 2018 | 2176 | 0.070 |
Why?
|
| Registries | 1 | 2016 | 2210 | 0.070 |
Why?
|
| Cause of Death | 3 | 2020 | 781 | 0.070 |
Why?
|
| Career Choice | 2 | 2006 | 212 | 0.070 |
Why?
|
| Radiology | 1 | 2013 | 427 | 0.070 |
Why?
|
| Acute Disease | 2 | 2009 | 2492 | 0.070 |
Why?
|
| Guidelines as Topic | 1 | 2009 | 359 | 0.070 |
Why?
|
| Conjunctival Neoplasms | 1 | 2008 | 124 | 0.070 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2019 | 3656 | 0.070 |
Why?
|
| Self Report | 3 | 2017 | 794 | 0.070 |
Why?
|
| Benchmarking | 2 | 2021 | 276 | 0.070 |
Why?
|
| Dogs | 1 | 2008 | 1082 | 0.070 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2009 | 342 | 0.070 |
Why?
|
| Organ Specificity | 1 | 2008 | 734 | 0.070 |
Why?
|
| Logistic Models | 3 | 2020 | 3429 | 0.070 |
Why?
|
| Breast Neoplasms | 2 | 2015 | 16244 | 0.060 |
Why?
|
| Health Surveys | 1 | 2007 | 395 | 0.060 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2021 | 4965 | 0.060 |
Why?
|
| Severity of Illness Index | 4 | 2017 | 4394 | 0.060 |
Why?
|
| Neoplasm Metastasis | 2 | 2018 | 5332 | 0.060 |
Why?
|
| Laryngectomy | 2 | 2017 | 244 | 0.060 |
Why?
|
| Larynx | 2 | 2017 | 147 | 0.060 |
Why?
|
| Diagnostic Imaging | 1 | 2013 | 1174 | 0.060 |
Why?
|
| Linear Models | 1 | 2008 | 1093 | 0.060 |
Why?
|
| Bayes Theorem | 2 | 2020 | 1060 | 0.060 |
Why?
|
| Cell Cycle | 2 | 2021 | 2134 | 0.060 |
Why?
|
| Kidney | 1 | 2012 | 2102 | 0.060 |
Why?
|
| Tomography Scanners, X-Ray Computed | 1 | 2004 | 89 | 0.060 |
Why?
|
| Rats | 1 | 2012 | 6397 | 0.060 |
Why?
|
| Biomarkers, Tumor | 2 | 2020 | 10726 | 0.060 |
Why?
|
| Remission Induction | 1 | 2010 | 3658 | 0.050 |
Why?
|
| Patient Outcome Assessment | 2 | 2015 | 245 | 0.050 |
Why?
|
| Educational Measurement | 1 | 2006 | 397 | 0.050 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2016 | 2435 | 0.050 |
Why?
|
| Chemotherapy, Adjuvant | 3 | 2016 | 4007 | 0.050 |
Why?
|
| Liver | 1 | 2012 | 3057 | 0.050 |
Why?
|
| Biopsy, Needle | 1 | 2007 | 1381 | 0.050 |
Why?
|
| Sleep Wake Disorders | 2 | 2019 | 372 | 0.050 |
Why?
|
| Tonsillectomy | 2 | 2016 | 121 | 0.050 |
Why?
|
| Motion | 2 | 2015 | 199 | 0.050 |
Why?
|
| Patient Care Planning | 1 | 2004 | 301 | 0.050 |
Why?
|
| Statistics, Nonparametric | 2 | 2016 | 982 | 0.050 |
Why?
|
| Human papillomavirus 16 | 2 | 2016 | 255 | 0.050 |
Why?
|
| Salivary Ducts | 1 | 2021 | 54 | 0.050 |
Why?
|
| Deubiquitinating Enzymes | 1 | 2021 | 35 | 0.050 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2021 | 3929 | 0.050 |
Why?
|
| Brain | 3 | 2021 | 4202 | 0.050 |
Why?
|
| Animals | 4 | 2021 | 61357 | 0.050 |
Why?
|
| Hep G2 Cells | 1 | 2021 | 146 | 0.050 |
Why?
|
| Professional Practice Location | 1 | 2020 | 15 | 0.050 |
Why?
|
| Geography, Medical | 1 | 2020 | 21 | 0.050 |
Why?
|
| Body Mass Index | 2 | 2021 | 2227 | 0.050 |
Why?
|
| Urban Health Services | 1 | 2020 | 34 | 0.050 |
Why?
|
| Caspase Inhibitors | 1 | 2020 | 95 | 0.050 |
Why?
|
| Biomimetics | 1 | 2020 | 37 | 0.050 |
Why?
|
| Rural Health Services | 1 | 2020 | 36 | 0.050 |
Why?
|
| HCT116 Cells | 1 | 2021 | 354 | 0.040 |
Why?
|
| Electric Impedance | 1 | 2021 | 101 | 0.040 |
Why?
|
| Smoking | 3 | 2016 | 2549 | 0.040 |
Why?
|
| Tongue | 1 | 2020 | 86 | 0.040 |
Why?
|
| Linear Energy Transfer | 1 | 2021 | 108 | 0.040 |
Why?
|
| Dipeptides | 1 | 2020 | 96 | 0.040 |
Why?
|
| Salivary Glands | 1 | 2020 | 139 | 0.040 |
Why?
|
| Homologous Recombination | 1 | 2021 | 188 | 0.040 |
Why?
|
| Mouth Mucosa | 1 | 2020 | 223 | 0.040 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 1 | 2022 | 339 | 0.040 |
Why?
|
| Temporal Lobe | 1 | 2021 | 190 | 0.040 |
Why?
|
| Quality Improvement | 2 | 2019 | 912 | 0.040 |
Why?
|
| Dental Impression Technique | 1 | 2019 | 16 | 0.040 |
Why?
|
| MCF-7 Cells | 1 | 2021 | 547 | 0.040 |
Why?
|
| Critical Pathways | 1 | 2021 | 160 | 0.040 |
Why?
|
| Peripheral Nerves | 1 | 2020 | 159 | 0.040 |
Why?
|
| Proteogenomics | 1 | 2020 | 110 | 0.040 |
Why?
|
| Smokers | 1 | 2020 | 154 | 0.040 |
Why?
|
| Intraoperative Period | 1 | 2019 | 251 | 0.040 |
Why?
|
| Case-Control Studies | 2 | 2019 | 6233 | 0.040 |
Why?
|
| Bevacizumab | 1 | 2023 | 967 | 0.040 |
Why?
|
| Physicians, Women | 1 | 2020 | 103 | 0.040 |
Why?
|
| Lymphocyte Count | 1 | 2020 | 485 | 0.040 |
Why?
|
| Leukocyte Count | 1 | 2020 | 727 | 0.040 |
Why?
|
| Salaries and Fringe Benefits | 1 | 2019 | 46 | 0.040 |
Why?
|
| Pyrimidinones | 1 | 2021 | 319 | 0.040 |
Why?
|
| Blood Vessels | 1 | 2020 | 232 | 0.040 |
Why?
|
| Equipment and Supplies | 1 | 2019 | 50 | 0.040 |
Why?
|
| Kallikreins | 1 | 2019 | 86 | 0.040 |
Why?
|
| Fluorouracil | 1 | 2023 | 1990 | 0.040 |
Why?
|
| Databases, Factual | 2 | 2018 | 2258 | 0.040 |
Why?
|
| Head | 1 | 2020 | 248 | 0.040 |
Why?
|
| Survivors | 2 | 2015 | 1021 | 0.040 |
Why?
|
| Breakthrough Pain | 1 | 2018 | 18 | 0.040 |
Why?
|
| Quality Control | 1 | 2019 | 461 | 0.040 |
Why?
|
| Gene Expression Profiling | 2 | 2021 | 5145 | 0.040 |
Why?
|
| Mitochondrial Proteins | 1 | 2020 | 377 | 0.040 |
Why?
|
| Artificial Intelligence | 1 | 2023 | 429 | 0.040 |
Why?
|
| Intestine, Large | 1 | 2018 | 32 | 0.040 |
Why?
|
| Pharynx | 1 | 2019 | 148 | 0.040 |
Why?
|
| Neck Pain | 1 | 2018 | 41 | 0.040 |
Why?
|
| Glutamate Carboxypeptidase II | 1 | 2017 | 16 | 0.040 |
Why?
|
| Caspases | 1 | 2020 | 672 | 0.040 |
Why?
|
| Program Evaluation | 1 | 2021 | 602 | 0.040 |
Why?
|
| Gallium Radioisotopes | 1 | 2017 | 62 | 0.040 |
Why?
|
| Liquid Biopsy | 1 | 2018 | 167 | 0.040 |
Why?
|
| HeLa Cells | 1 | 2021 | 1683 | 0.040 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2020 | 622 | 0.040 |
Why?
|
| Drug Synergism | 1 | 2021 | 1355 | 0.040 |
Why?
|
| Retreatment | 1 | 2018 | 449 | 0.040 |
Why?
|
| Databases, Genetic | 1 | 2020 | 758 | 0.040 |
Why?
|
| Time | 1 | 2017 | 182 | 0.040 |
Why?
|
| HEK293 Cells | 1 | 2021 | 1458 | 0.040 |
Why?
|
| Disease Models, Animal | 2 | 2021 | 7317 | 0.030 |
Why?
|
| Antigens, Surface | 1 | 2017 | 304 | 0.030 |
Why?
|
| Survivorship | 1 | 2017 | 116 | 0.030 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2023 | 1580 | 0.030 |
Why?
|
| Margins of Excision | 1 | 2018 | 315 | 0.030 |
Why?
|
| Teaching Rounds | 1 | 2016 | 37 | 0.030 |
Why?
|
| Evaluation Studies as Topic | 1 | 2016 | 449 | 0.030 |
Why?
|
| Steroids | 1 | 2018 | 372 | 0.030 |
Why?
|
| Palate, Soft | 1 | 2016 | 32 | 0.030 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2021 | 866 | 0.030 |
Why?
|
| Stress, Physiological | 1 | 2019 | 489 | 0.030 |
Why?
|
| Area Under Curve | 1 | 2017 | 731 | 0.030 |
Why?
|
| Tomography, Emission-Computed | 1 | 2016 | 334 | 0.030 |
Why?
|
| Interviews as Topic | 1 | 2017 | 518 | 0.030 |
Why?
|
| DNA Replication | 1 | 2019 | 768 | 0.030 |
Why?
|
| Urogenital Neoplasms | 1 | 2016 | 118 | 0.030 |
Why?
|
| Indoles | 1 | 2020 | 1029 | 0.030 |
Why?
|
| Hospital Mortality | 1 | 2021 | 1233 | 0.030 |
Why?
|
| Medical Audit | 1 | 2016 | 194 | 0.030 |
Why?
|
| Biological Transport | 1 | 2016 | 630 | 0.030 |
Why?
|
| Etoposide | 1 | 2017 | 907 | 0.030 |
Why?
|
| Odds Ratio | 1 | 2020 | 2299 | 0.030 |
Why?
|
| Central Nervous System | 1 | 2017 | 450 | 0.030 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2020 | 1276 | 0.030 |
Why?
|
| Medically Uninsured | 1 | 2015 | 107 | 0.030 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2021 | 1462 | 0.030 |
Why?
|
| Computational Biology | 1 | 2021 | 1295 | 0.030 |
Why?
|
| Up-Regulation | 1 | 2020 | 2413 | 0.030 |
Why?
|
| Health Personnel | 1 | 2019 | 650 | 0.030 |
Why?
|
| Carcinoma, Acinar Cell | 1 | 2014 | 87 | 0.030 |
Why?
|
| Cetuximab | 1 | 2015 | 474 | 0.030 |
Why?
|
| Patient Protection and Affordable Care Act | 1 | 2015 | 109 | 0.030 |
Why?
|
| Confidence Intervals | 1 | 2015 | 747 | 0.030 |
Why?
|
| Sexuality | 1 | 2013 | 36 | 0.030 |
Why?
|
| Histones | 1 | 2021 | 1512 | 0.030 |
Why?
|
| Pain Measurement | 1 | 2018 | 1021 | 0.030 |
Why?
|
| Mitochondria | 1 | 2020 | 1292 | 0.030 |
Why?
|
| Length of Stay | 1 | 2021 | 1997 | 0.030 |
Why?
|
| Tosyl Compounds | 1 | 2013 | 38 | 0.030 |
Why?
|
| Postoperative Care | 1 | 2017 | 726 | 0.030 |
Why?
|
| Insurance, Health | 1 | 2015 | 261 | 0.030 |
Why?
|
| Symptom Assessment | 1 | 2015 | 271 | 0.030 |
Why?
|
| Spinal Cord Neoplasms | 1 | 2014 | 155 | 0.030 |
Why?
|
| Radiation Monitoring | 1 | 2013 | 53 | 0.030 |
Why?
|
| Phosphorylation | 1 | 2021 | 4907 | 0.030 |
Why?
|
| Qualitative Research | 1 | 2016 | 638 | 0.030 |
Why?
|
| Emergency Service, Hospital | 1 | 2021 | 1257 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2021 | 5056 | 0.030 |
Why?
|
| Cells, Cultured | 1 | 2021 | 5657 | 0.030 |
Why?
|
| Orchiectomy | 1 | 2013 | 211 | 0.030 |
Why?
|
| Protein Binding | 1 | 2019 | 3472 | 0.030 |
Why?
|
| Postoperative Complications | 2 | 2021 | 5674 | 0.030 |
Why?
|
| Medicaid | 1 | 2015 | 306 | 0.030 |
Why?
|
| Neck | 1 | 2015 | 394 | 0.030 |
Why?
|
| Kinetics | 1 | 2015 | 2206 | 0.030 |
Why?
|
| Pyrazoles | 1 | 2021 | 1551 | 0.030 |
Why?
|
| Carboplatin | 1 | 2015 | 889 | 0.030 |
Why?
|
| Sickness Impact Profile | 1 | 2012 | 138 | 0.020 |
Why?
|
| Patient Satisfaction | 1 | 2017 | 924 | 0.020 |
Why?
|
| Perioperative Care | 1 | 2016 | 448 | 0.020 |
Why?
|
| Weight Loss | 1 | 2016 | 628 | 0.020 |
Why?
|
| Hospitalization | 1 | 2021 | 2170 | 0.020 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2015 | 586 | 0.020 |
Why?
|
| Maximum Tolerated Dose | 1 | 2015 | 1329 | 0.020 |
Why?
|
| Brain Stem | 1 | 2012 | 185 | 0.020 |
Why?
|
| Cognition | 1 | 2017 | 969 | 0.020 |
Why?
|
| Receptor, ErbB-2 | 1 | 2021 | 2658 | 0.020 |
Why?
|
| Health Expenditures | 1 | 2013 | 202 | 0.020 |
Why?
|
| Herpesvirus 4, Human | 1 | 2015 | 959 | 0.020 |
Why?
|
| Gastrointestinal Tract | 1 | 2014 | 322 | 0.020 |
Why?
|
| Melanoma | 1 | 2008 | 5599 | 0.020 |
Why?
|
| Transcription, Genetic | 1 | 2019 | 3328 | 0.020 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2016 | 551 | 0.020 |
Why?
|
| History, 21st Century | 1 | 2013 | 410 | 0.020 |
Why?
|
| Models, Biological | 1 | 2019 | 3186 | 0.020 |
Why?
|
| Technetium Tc 99m Sulfur Colloid | 1 | 2011 | 113 | 0.020 |
Why?
|
| Adaptation, Physiological | 1 | 2012 | 340 | 0.020 |
Why?
|
| Anilides | 1 | 2013 | 295 | 0.020 |
Why?
|
| Pain | 1 | 2019 | 1701 | 0.020 |
Why?
|
| Early Detection of Cancer | 1 | 2019 | 1344 | 0.020 |
Why?
|
| Carbon | 1 | 2011 | 165 | 0.020 |
Why?
|
| Neoplasms, Second Primary | 1 | 2019 | 1388 | 0.020 |
Why?
|
| Quinazolines | 1 | 2015 | 956 | 0.020 |
Why?
|
| Molecular Targeted Therapy | 1 | 2020 | 2396 | 0.020 |
Why?
|
| Cluster Analysis | 1 | 2012 | 1076 | 0.020 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2014 | 626 | 0.020 |
Why?
|
| Gold | 1 | 2011 | 267 | 0.020 |
Why?
|
| Radionuclide Imaging | 1 | 2011 | 654 | 0.020 |
Why?
|
| Rhabdomyosarcoma | 1 | 2013 | 342 | 0.020 |
Why?
|
| Mice | 2 | 2021 | 35421 | 0.020 |
Why?
|
| Electronic Health Records | 1 | 2016 | 854 | 0.020 |
Why?
|
| Intestines | 1 | 2013 | 726 | 0.020 |
Why?
|
| Spinal Cord | 1 | 2012 | 717 | 0.020 |
Why?
|
| Nitriles | 1 | 2013 | 939 | 0.020 |
Why?
|
| DNA-Binding Proteins | 1 | 2021 | 4992 | 0.020 |
Why?
|
| Adaptation, Psychological | 1 | 2012 | 783 | 0.020 |
Why?
|
| Analgesics, Opioid | 1 | 2018 | 1467 | 0.020 |
Why?
|
| Efficiency | 1 | 2007 | 93 | 0.020 |
Why?
|
| Cell Proliferation | 1 | 2019 | 7232 | 0.020 |
Why?
|
| Guideline Adherence | 1 | 2011 | 626 | 0.020 |
Why?
|
| Likelihood Functions | 1 | 2007 | 240 | 0.020 |
Why?
|
| Disease Management | 1 | 2011 | 1092 | 0.020 |
Why?
|
| Stress, Psychological | 1 | 2012 | 1038 | 0.020 |
Why?
|
| Private Practice | 1 | 2005 | 33 | 0.020 |
Why?
|
| Personnel Staffing and Scheduling | 1 | 2005 | 91 | 0.010 |
Why?
|
| Sex Distribution | 1 | 2005 | 497 | 0.010 |
Why?
|
| Lung | 1 | 2015 | 3284 | 0.010 |
Why?
|
| Amifostine | 1 | 2004 | 99 | 0.010 |
Why?
|
| Lymph Node Excision | 1 | 2011 | 2068 | 0.010 |
Why?
|
| Sentinel Lymph Node Biopsy | 1 | 2011 | 1464 | 0.010 |
Why?
|
| Radiation-Protective Agents | 1 | 2004 | 129 | 0.010 |
Why?
|
| Glioma | 1 | 2014 | 1986 | 0.010 |
Why?
|
| Chi-Square Distribution | 1 | 2005 | 1307 | 0.010 |
Why?
|
| Models, Statistical | 1 | 2007 | 1186 | 0.010 |
Why?
|
| Mutation | 1 | 2020 | 15917 | 0.010 |
Why?
|
| Sex Factors | 1 | 2005 | 2180 | 0.010 |
Why?
|
| Brain Neoplasms | 1 | 2014 | 4968 | 0.010 |
Why?
|